EUVIMEDEUVIMED entdecken
Crossref

Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study

Kai-Chun Wang iD, Yi-Syuan Sun, Hung-Cheng Tsai iD, Hsien-Tzung Liao iD, Chien-Chih Lai iD, Wei-Sheng Chen, Ling-Ying Lu iD, Ming-Han Chen iD

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Kai-Chun Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy-Immunology-Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, HLA-B27 Antigen, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the link between the administration of biologic disease-modifying antirheumatic drugs (bDMARDs) and the risk of malignancy in human leukocyte antigen B27 (HLA-B27)-positive patients with ankylosing spondylitis (AS) experiencing sustained inflammation.

Methods

Between 2006 and 2021, 1445 HLA-B27-positive patients with AS were retrospectively evaluated. Among them, 112 patients required bDMARD therapy. The study compared conventional therapy with bDMARDs and investigated the risk factors for developing malignancies.

Results

During 8253 patient-years of follow-up, 38 (2.6%) patients developed various malignancies, including lung, liver, breast, and colon cancer. The risk of malignancy was significantly higher in the bDMARD-treated group compared to PS-matched groups receiving conventional synthetic DMARDs (csDMARD) and non-steroidal anti-inflammatory drugs. The cumulative risk of malignancies increased significantly after 6 years of follow-up. All patients who developed malignancy after bDMARD therapy received tumor necrosis factor-α inhibitors. Requiring bDMARD therapy, requiring bDMARDs in combination with csDMARD therapy, and being diagnosed with AS after 30 years of age were independent risk factors for developing malignancy.

Conclusions

HLA-B27-positive AS patients with sustained inflammation requiring biologic therapy, particularly if diagnosed after age 30, may have an increased risk of malignancy. Regular cancer screenings are advisable for these patients while undergoing biologic treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spondylitis, AnkylosingHLA-B27 AntigenAntirheumatic AgentsBiological ProductsNeoplasmsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedRisk FactorsInflammation

Stichwörter der Autor:innen

Ankylosing spondylitisbiologic therapyhuman leukocyte antigen-B27malignancytumor necrosis factor-α inhibitors

Substanzen

HLA-B27 AntigenAntirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Division of Allergy-Immunology-Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
  • The Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
  • School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

ORCID-Profile: Kai-Chun Wang, Hung-Cheng Tsai, Hsien-Tzung Liao, Chien-Chih Lai, Ling-Ying Lu, Ming-Han Chen

Zitieren

APA

Wang, K. C., Sun, Y. S., Tsai, H. C., Liao, H. T., Lai, C. C., Chen, W. S., Lu, L. Y., & Chen, M. H. (2024). Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study. Modern Rheumatology. https://doi.org/10.1093/mr/roae004

Vancouver

Wang KC, Sun YS, Tsai HC, Liao HT, Lai CC, Chen WS, et al. Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study. Modern Rheumatology. 2024. doi:10.1093/mr/roae004

BibTeX
@article{Wang2024,
  author = {Wang, Kai-Chun and Sun, Yi-Syuan and Tsai, Hung-Cheng and Liao, Hsien-Tzung and Lai, Chien-Chih and Chen, Wei-Sheng and Lu, Ling-Ying and Chen, Ming-Han},
  title = {Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae004}
}
Kostenlos starten →